Treatment
Irinotecan clinical trials
We’re tracking 200 recruiting studies that include Irinotecan, each written for real people, not researchers, below.
Recruiting studies
- NCT05688215RecruitingPhase 1/Phase 2
Zimberelimab and quemliclustat with chemotherapy for pancreatic cancer
This trial studies how well zimberelimab and quemliclustat work together with standard chemotherapy for people with borderline resectable or locally advanced pancreatic cancer. It may help shrink the tumor and make treatment more effective before or around the time surgery is considered for some patients.
Los Angeles, CaliforniaAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05669339RecruitingPhase 2
AI-guided dosing study for advanced liver cancer patients
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Gainesville, FloridaAges 18–99 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05391126Recruiting
Genetic test helps choose drug dosing for pancreas or colon cancer
This study tests whether using a genetic test to guide medication doses works better than standard dosing for people with certain pancreas or colon cancers. It may help by tailoring treatment more precisely to your tumor’s genetic features.
Lexington, KentuckyAges 18 years+ - NCT05438459RecruitingPhase 1/Phase 2
GAIA-102 for advanced stomach or pancreatic cancer with ascites
This trial tests a new drug, GAIA-102, given directly into the abdomen to treat advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The goal is to see if it can slow the cancer or improve symptoms.
Fukuoka, FukuokaAges 20 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Orange, CaliforniaAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT05385861Enrolling by invitationPhase 1/Phase 2
ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Kaohsiung CityAges 20–80 - NCT05412082RecruitingPhase 1
Smart chemo and radiation plan for locally advanced rectal cancer
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
Miami, FloridaAges 18 years+ - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT05384821RecruitingPhase 1/Phase 2
Oral low-dose chemotherapy for relapsed Wilms tumor
This Phase 1/2 trial studies metronomic (very low, steady) chemotherapy taken by mouth or through a feeding tube for children with Wilms tumor that has come back or not responded to earlier treatment. It aims to shrink measurable tumors with better long-term tolerability than standard chemotherapy.
AmiensAges 1.5 years–17 years - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05314998RecruitingPhase 3
Chemo after fully removed pancreatic cancer, guided by gene testing
This Phase 3 study tests whether people with pancreatic cancer should get standard chemo or a chemo plan guided by a tumor gene/RNA test after surgery. It aims to see if the right chemo choice for your tumor biology can improve outcomes after your tumor is removed.
AachenAges 18–79 - NCT05203172RecruitingPhase 4
Continued access to encorafenib and binimetinib for prior trial participants
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
Phoenix, ArizonaAges 18 years+ - NCT05062317RecruitingPhase 2
Blood test-guided chemotherapy after liver tumor removal
This trial uses a blood test (ctDNA, a sign of cancer cells shedding into the blood) to help guide chemotherapy after surgery to remove colorectal liver metastases. It may help patients get the right chemotherapy plan after their operation, potentially based on whether cancer material is still detectable.
Houston, TexasAges 18 years+ - NCT05004116RecruitingPhase 1/Phase 2
Repotrectinib plus chemotherapy for relapsed solid tumors in youth
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
New York, New YorkAges 1–25 - NCT04920032RecruitingPhase 1
Blood test–guided extra treatment for colon cancer recurrence risk
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Orange, CaliforniaAges 18 years+ - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Chicago, IllinoisAges 6 months–30 years - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04478292RecruitingPhase 3
New treatment strategy for children with newly diagnosed liver cancer
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT04342910RecruitingPhase 3
Test camrelizumab plus apatinib for advanced stomach cancer
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
BeijingAges 18 years+
Common questions
- Are there clinical trials studying Irinotecan?
- Yes. Clin2 currently lists 200 recruiting studies that include Irinotecan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Irinotecan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Irinotecan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Irinotecan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.